You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
据报科兴生物候选疫苗可快速触发免疫反应 惟抗体量较康复者体内为少
阿思达克 11-18 13:15
据英国《金融时报》报道,由中国科兴生物(Sinovac)开发的新冠候选疫苗可快速触发免疫反应,但产生的抗体量较新冠康复者体内抗体量为少。

有研究考量科兴生物疫苗第一及第二阶段的结果,该疫苗采用已化学去活跃化病毒版本以触发免疫反应。研究发现接种最後一剂疫苗28日後,志愿者体内抗体量较新冠康复者体内抗体量为少。

不过,研究人员引述其他研究指,自然新冠感染带来的抗体会随着时间减少,并有再感染的小量案例,意味「免疫记忆」在避免再度感染上有重要角色。抗体量水平本身未必足以让疫苗取得成功,但发现了对新冠病毒的可召回的特定免疫反应。而快速免疫反应亦意味疫苗或可作紧急采用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account